USP38 and cancer: Since loss of H2Bub has been reported in the pathogenesis of multiple cancers, including breast, colorectal, lung, and parathyroid cancers,[53] the deubiquitinase USP38 might be a prominent epigenetic therapeutic target for inflammation, autoimmunity, and cancer in the future.